Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Payables (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Payables for 12 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 19.09% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, up 19.09%, and an annual FY2024 reading of $2.1 million, up 334.64% over the prior year.
  • Payables was $2.0 million for Q3 2025 at Arcadia Biosciences, up from $1.6 million in the prior quarter.
  • Across five years, Payables topped out at $5.2 million in Q2 2021 and bottomed at $485000.0 in Q4 2023.
  • Average Payables over 5 years is $2.5 million, with a median of $2.1 million recorded in 2024.
  • The sharpest move saw Payables crashed 46.41% in 2023, then soared 334.64% in 2024.
  • Year by year, Payables stood at $1.4 million in 2021, then crashed by 35.86% to $905000.0 in 2022, then plummeted by 46.41% to $485000.0 in 2023, then skyrocketed by 334.64% to $2.1 million in 2024, then fell by 4.41% to $2.0 million in 2025.
  • Business Quant data shows Payables for RKDA at $2.0 million in Q3 2025, $1.6 million in Q2 2025, and $1.9 million in Q1 2025.